Strategies to improve patient-reported outcome completion rates in longitudinal studies

[1]  M. Jarden,et al.  Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma , 2019, British journal of haematology.

[2]  J. Temel,et al.  Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Girgis,et al.  Study protocol for a controlled trial of an eHealth system utilising patient reported outcome measures for personalised treatment and care: PROMPT-Care 2.0 , 2018, BMC cancer.

[4]  E. Basch.  Patient-reported outcomes: an essential component of oncology drug development and regulatory review. , 2018, The Lancet. Oncology.

[5]  Joanna Coast,et al.  Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension , 2018, JAMA.

[6]  M. King,et al.  A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data , 2018, Clinical trials.

[7]  M. Stockler,et al.  The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training , 2017, Contemporary clinical trials communications.

[8]  P. Butow,et al.  Ovarian cancer study dropouts had worse health‐related quality of life and psychosocial symptoms at baseline and over time , 2017, Asia-Pacific journal of clinical oncology.

[9]  M. Kris,et al.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment , 2017, JAMA.

[10]  C. Andersen,et al.  A systematic review of health‐related quality of life in longitudinal studies of myeloma patients , 2017, European journal of haematology.

[11]  L. Collette,et al.  Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. , 2016, The Lancet. Oncology.

[12]  R. Siegert,et al.  Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta‐analysis , 2016, European journal of haematology.

[13]  T. Plesner,et al.  The Danish National Multiple Myeloma Registry , 2016, Clinical epidemiology.

[14]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[15]  Melanie Calvert,et al.  Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review , 2016, BMJ Open.

[16]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[17]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[18]  A. Vangsted,et al.  Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database , 2015, American journal of hematology.

[19]  K. Anderson,et al.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. , 2015, Blood.

[20]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[21]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[22]  G. Kemmler,et al.  Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden , 2014, BMC Cancer.

[23]  Melanie L Bell,et al.  Practical and statistical issues in missing data for longitudinal patient-reported outcomes , 2014, Statistical methods in medical research.

[24]  J. Snowden,et al.  Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. , 2013, Journal of pain and symptom management.

[25]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[26]  F. Davies,et al.  Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study , 2013, Supportive Care in Cancer.

[27]  H. Goldschmidt,et al.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[28]  Amy P Abernethy,et al.  Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[30]  P. Wen,et al.  Management of treatment-emergent peripheral neuropathy in multiple myeloma , 2012, Leukemia.

[31]  R. Wäsch,et al.  Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score , 2011, Blood cancer journal.

[32]  A. Hamidin,et al.  Quality of life among patients with hematological cancer in a Malaysian hospital. , 2011, The Medical journal of Malaysia.

[33]  M. Mateos.  Management of treatment-related adverse events in patients with multiple myeloma. , 2010, Cancer treatment reviews.

[34]  D. Fairclough.  Design and Analysis of Quality of Life Studies in Clinical Trials, Second Edition , 2010 .

[35]  M. Groenvold,et al.  Health related quality of life in a nationally representative sample of haematological patients , 2009, European journal of haematology.

[36]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[37]  J. Bladé,et al.  Changing paradigms in the treatment of multiple myeloma , 2009, Haematologica.

[38]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[39]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[40]  R. Hájek,et al.  An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. , 2007, European journal of cancer.

[41]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  K. Hoang-Xuan,et al.  The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. , 2005, European journal of cancer.

[43]  G. Juliusson,et al.  Early response predicts thalidomide efficiency in patients with advanced multiple myeloma * , 2004, British journal of haematology.

[44]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[45]  D. Fairclough.  Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.

[46]  T. F. Andersen,et al.  The Danish National Hospital Register. A valuable source of data for modern health sciences. , 1999, Danish medical bulletin.

[47]  D. Osoba,et al.  Missing quality of life data in cancer clinical trials: serious problems and challenges. , 1998, Statistics in medicine.

[48]  D. Cella,et al.  Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. , 1998, Statistics in medicine.

[49]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[50]  S. Kaasa,et al.  Measurement of health‐related quality of life in multiple myeloma , 1996, British journal of haematology.

[51]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[52]  L. Laliberte,et al.  The Karnofsky performance status scale: An examination of its reliability and validity in a research setting , 1984, Cancer.

[53]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[54]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[55]  M. Jarden,et al.  Quality of life in newly diagnosed and relapsed Danish multiple myeloma patients , 2018 .

[56]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[57]  Lao Juan,et al.  Development and Validation of a Scale for Measuring Instructors' Attitudes toward Concept-Based or Reform-Oriented Teaching of Introductory Statistics in the Health and Behavioral Sciences , 2010, 1007.3219.

[58]  J. Shah,et al.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) , 2014, Leukemia.

[59]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[60]  D. Osoba,et al.  Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. , 2005, European journal of cancer.

[61]  T. G. S. Group,et al.  Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support , 2001, Medical oncology.

[62]  D. Machin,et al.  A clinical model for quality of life assessment in cancer patients receiving chemotherapy. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[64]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.